Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Ori Biotech, a UK-based cell and gene therapy manufacturing spinout of University College London, closed a £7m ($9.4m) seed round yesterday backed by Amadeus Capital Partners, Delin Ventures and Kindred Capital together with an unnamed family office and undisclosed existing angel investors. The spinout was founded in 2015 by Chris Mason and Farlan Veraitch, professor and senior lecturer in UCL’s biochemical engineering department respectively, to commercialise a platform for building new personalised drugs based on cellular and genetic insights. Ori will…
